Our results indicate that knocking down the expression of COX-2 by either using a COX-2 selective inhibitor or COX-2 siRNA, reversed TRAIL-resistant phenotype and the incidence of cells with stem cell phenotype in breast cancer spheroids. The gene discussed is TNFSF10; the disease is breast carcinoma.